Compare GOLF & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOLF | IOVA |
|---|---|---|
| Founded | 1910 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 968.6M |
| IPO Year | 2016 | N/A |
| Metric | GOLF | IOVA |
|---|---|---|
| Price | $82.63 | $2.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $74.86 | $10.45 |
| AVG Volume (30 Days) | 283.9K | ★ 11.3M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 24.30 | N/A |
| EPS | ★ 3.64 | N/A |
| Revenue | ★ $2,526,675,000.00 | $250,425,000.00 |
| Revenue This Year | $5.17 | $60.71 |
| Revenue Next Year | $2.52 | $59.52 |
| P/E Ratio | $22.80 | ★ N/A |
| Revenue Growth | 4.20 | ★ 175.62 |
| 52 Week Low | $55.31 | $1.64 |
| 52 Week High | $86.19 | $8.15 |
| Indicator | GOLF | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 50.04 | 64.22 |
| Support Level | $81.50 | $2.08 |
| Resistance Level | $86.15 | $2.99 |
| Average True Range (ATR) | 1.70 | 0.17 |
| MACD | -0.32 | 0.06 |
| Stochastic Oscillator | 30.87 | 77.47 |
Acushnet Holdings Corp is engaged in the design, development, manufacture, and distribution of golf products. Its product category includes golf balls, golf shoes, golf clubs, wedges, putters, golf gloves, golf gear and golf wear, and others. These products are offered through different brands such as Titleist, FootJoy, Scotty Cemeron, Vokey Design, Pinnacle, KJUS, and others. The company's reportable segments are Titleist golf equipment, FootJoy golf wear, and Gofl gear. A majority of its revenue is generated by the Titleist golf equipment segment. Geographically, the company generates maximum revenue from the United States, followed by Europe, Middle East and Asia (EMEA), Japan, Korea, and the Rest of the world.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.